Share Prices & Company Research

Stockbroking

Hemogenyx Pharmaceuticals

Current Price 1.98p Bid 1.80p Ask 2.00p Change 0.00%
Last Updated: 13/11/2019 02:37. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Hemogenyx Pharmaceuticals plc (formerly Silver Falcon plc) with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liege. Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

Financial Highlights Year Ended 31/12/2018

Turnover
£0.00m
Operating Profit
£-1.62m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-4.63

Key Personnel

Dr Vladislav Sandler
Chief Executive Officer
Sir Marc Feldmann
Executive Chairman
Alexis Sandler
Non-Executive Director
Peter Redmond
Non-Executive Director

Stock Details

EPIC
HEMO
ISIN
GB00BYX3WZ24
Shares in Issue
361,242,853
Market cap
£6.86m
Sector

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
0.00p
Bid Price
1.80p
Ask Price
2.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
1.90p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
3.75p
52 Week Low
1.90p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Hemogenyx Pharmaceuticals Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
0.2
0.2
Intangible Assets & Goodwill
0.3
0.3
Investments & Other Non-Current Assets
0.0
0.0
Total Non-Current Assets
0.5
0.5
Inventory
0.0
0.0
Trade & Receivables
0.1
0.1
Cash & Receivables
1.8
1.9
Other Current Assets & Assets Held for Resale
0.0
0.0
Total Assets
2.3
2.4

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
0.2
0.3
Long Term Liabilities
1.2
0.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1.3
0.3

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
1.0
2.1

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
3.6
3.6
Minority Interests
0.0
0.0
Retained Earnings
-4.5
-3.0
Share Premium Account
7.3
7.3
Other Equity
-5.5
-5.8
Total Equity
1.0
2.1

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
-1.4
-0.5
Cashflow Before Financing
-1.4
0.6
Increase / Decrease in Cash
-0.2
1.8

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
0.0
0.0
Cost of Sales
0.0
0.0
Gross Profit
0.0
0.0
Operating Profit
-1.6
-0.8
Pre-Tax Profit
-1.5
-2.4
Profit / Loss for the Year
-1.5
-2.4
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.